logo-loader
viewClinigen Group PLC

Clinigen Group sees significant opportunities with Proleukin acquisition

Shaun Chilton, chief executive of Clinigen Group PLC (LON:CLIN), discusses with Proactive's Andrew Scott the speciality pharma company's decision to acquire the global rights to Proleukin for an undisclosed sum from Novartis.

The drug is used to treat the metastatic forms of renal cell carcinoma and melanoma and the plan is to work with the healthcare professionals to revitalise the product.

Updating on recent trading, Chilton says revenues for the year ended June 30 grew by 27% on a constant currency basis, while gross profit advanced by 16% on the same measurement.

Quick facts: Clinigen Group PLC

Price: 870 GBX

AIM:CLIN
Market: AIM
Market Cap: £1.16 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Clinigen Group PLC named herein, including the promotion by the Company of Clinigen Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Clinigen and Bristol-Myers Squibb sign extended partnership agreement in...

Shaun Chilton, CEO of Clinigen Group PLC (LON:CLIN) tells Proactive that agreement with Bristol-Myers Squibb proves two things. “One, that pharmaceutical companies, even the biggest ones, are looking to partner in certain parts of the world in terms of commercialising their medicines,“...

on 1/6/18

2 min read